While still in its infancy, and convoluted by the various interconnected pathways, studies investigating the effects of GLP-1 therapies in the adipose tissue of patients with obesity show promise, with trials replicating in vitro studies, and indicating a potential long term benefit of GLP-1R agonists therapies also in this important tissue. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.